Thymosin beta 4 induced phenotypic changes in Molt-4 leukemic cell line.

Kokkinopoulos D, Perez S, Papamichail M

Blut1 Jun 1985Cited by 12 (Europe PMC)

PMID2988673DOI10.1007/bf00320927PepBankPUB-02988673

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In Molt-4 cells, thymosin beta‑4 reduced expression of a T-cell lineage specific antigen detected by the WT 1 antibody.
In plain wordsIn cells, thymosin beta‑4 lowered a marker of T-cell lineage on leukemic T cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseT-cell lineage antigen (WT 1) expression
Study
humann: not reported in source
Molt-4 human T-cell line
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
Thymosin beta 4 induced Molt-4 cells to reduce the expression of a T-cell lineage specific antigen, with preferential expression on T blast-cells, detected by WT 1 monoclonal antibody.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867301
02LabIn vitro (cells)Mechanism
In Molt-4 cells, thymosin beta‑4 increased sheep erythrocyte rosettes.
In plain wordsIn cells, thymosin beta‑4 increased the number of sheep red blood cell rosettes formed by Molt-4 cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseSheep erythrocyte rosettes
Study
humann: not reported in source
Molt-4 human T-cell line
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
Thymosin beta 4 also induced an increase in sheep erythrocyte rosettes and PNA binding as well as an increased expression of OKT 11 A and OKT 8 in Molt-4 cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867302
03LabIn vitro (cells)Mechanism
In Molt-4 cells, thymosin beta‑4 increased peanut agglutinin binding.
In plain wordsIn cells, thymosin beta‑4 increased peanut agglutinin binding.
Peptide
Thymosin beta-4 (human)
Outcome
IncreasePeanut agglutinin (PNA) binding
Study
humann: not reported in source
Molt-4 human T-cell line
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
Thymosin beta 4 also induced an increase in sheep erythrocyte rosettes and PNA binding as well as an increased expression of OKT 11 A and OKT 8 in Molt-4 cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867303
04LabIn vitro (cells)Mechanism
In Molt-4 cells, thymosin beta‑4 increased expression of OKT 11A.
In plain wordsIn cells, thymosin beta‑4 increased a T-cell marker named OKT 11A.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseOKT 11A expression
Study
humann: not reported in source
Molt-4 human T-cell line
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
Thymosin beta 4 also induced an increase in sheep erythrocyte rosettes and PNA binding as well as an increased expression of OKT 11 A and OKT 8 in Molt-4 cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867304
05LabIn vitro (cells)Mechanism
In Molt-4 cells, thymosin beta‑4 increased expression of OKT 8.
In plain wordsIn cells, thymosin beta‑4 increased a T-cell marker named OKT 8.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseOKT 8 expression
Study
humann: not reported in source
Molt-4 human T-cell line
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
Thymosin beta 4 also induced an increase in sheep erythrocyte rosettes and PNA binding as well as an increased expression of OKT 11 A and OKT 8 in Molt-4 cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867305
06LabIn vitro (cells)Mechanism
In Molt-4 cells, TdT was unchanged by thymosin beta‑4.
In plain wordsIn cells, thymosin beta‑4 did not change the enzyme TdT.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeTerminal deoxynucleotidyl transferase (TdT)
Study
humann: not reported in source
Molt-4 human T-cell line
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
TdT was found to be unchanged, however.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867306
07LabIn vitro (cells)Mechanism
In Molt-4 cells, OKT 3 expression showed no change with thymosin beta‑4 compared with controls.
In plain wordsIn cells, thymosin beta‑4 did not change the marker OKT 3 compared with controls.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeOKT 3 expression
Study
humann: not reported in source
Molt-4 human T-cell line
Comparator
Controls
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
Analysis of thymosin beta 4-treated cells with other monoclonal antibodies (OKT 3, OKT 6, OKT 9) showed no change when compared to controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867307
08LabIn vitro (cells)Mechanism
In Molt-4 cells, OKT 6 expression showed no change with thymosin beta‑4 compared with controls.
In plain wordsIn cells, thymosin beta‑4 did not change the marker OKT 6 compared with controls.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeOKT 6 expression
Study
humann: not reported in source
Molt-4 human T-cell line
Comparator
Controls
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
Analysis of thymosin beta 4-treated cells with other monoclonal antibodies (OKT 3, OKT 6, OKT 9) showed no change when compared to controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867308
09LabIn vitro (cells)Mechanism
In Molt-4 cells, OKT 9 expression showed no change with thymosin beta‑4 compared with controls.
In plain wordsIn cells, thymosin beta‑4 did not change the marker OKT 9 compared with controls.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeOKT 9 expression
Study
humann: not reported in source
Molt-4 human T-cell line
Comparator
Controls
Outcome group
Immune response · Immune and inflammation
Studied dose
nanogram concentrations · up to 16 daysAs given in this study (human).
Source sentences
Summary
Analysis of thymosin beta 4-treated cells with other monoclonal antibodies (OKT 3, OKT 6, OKT 9) showed no change when compared to controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Thymosin beta 4 was tested for its ability to induce phenotypic changes in the human T-cell line Molt-4. Cells were cultured with nanogram concentrations of thymosin beta 4 for up to 16 days and were analyzed with a panel of monoclonal antibodies, sheep erythrocyte rosetting, peanut agglutinin bindi…
Report a problemFND-0298867309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.